SEC Form 4/A · accession 0001725092-26-000009
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Shao-Lee Lin
Officer — Chief Executive Officer · Director
Period of report
Jun 1, 2026
Accepted (ET)
Jul 30, 2026 · 4:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001645460
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Funded Warrants (Right to Buy)F3,F4,F2 | $0.001 | Jun 1, 2026 | A | 90,906 | A | Jun 1, 2026 | — | Common Stock | 90,906 | 90,906 | I |
| Common Stock Warrants (Right to Buy)F3,F4 | $11.00 | Jun 1, 2026 | A | 45,453 | A | Jun 1, 2026 | May 4, 2031 | Common Stock | 45,453 | 45,453 | I |
Explanation of responses
- F1This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged.
- F2The securities do not have an expiration date.
- F3On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.
- F4The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.